{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":">450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":">480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":">500 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"12-lead electrocardiogram was obtained at indicated time points using an automated electrocardiogram machine that measured QTcF interval. The number of participants with maximum post-Baseline ECG value exceeding the following limits have been reported: QTcF interval \\>450 and \\<= 480 milliseconds (msec) and \\>500 msec.","groups":[{"description":"Participants received Niraparib 300 mg once daily orally.","id":"OG000","title":"QTc Sub-study: Niraparib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"At Baseline (Cycle 1 Day 1, each cycle was of 28 days)","title":"Number of Participants With Maximum Post-Baseline QT Interval Corrected by Fridericia's Formula (QTcF) Greater Than Pre-specified Thresholds","type":"SECONDARY","unitOfMeasure":"Participants"}